In osteosarcoma, TIGIT+ T cells are highly present and, when treated ex vivo with an anti-TIGIT antibody, acquire cytotoxic activity against neoplastic cells in vitro, thus supporting the potential clinical application of TIGIT blockade for children affected by this cancer [188]. Here, TIGIT is linked to osteosarcoma.